Published in Endocr Rev on February 01, 2004
PRecisiOn MEdicine to Target Frailty of Endocrine-metabolic Origin (PROMETEO) | NCT04856683
Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev (2008) 2.64
Acromegaly pathogenesis and treatment. J Clin Invest (2009) 2.19
Acromegaly. Orphanet J Rare Dis (2008) 1.61
Clinical, quality of life, and economic value of acromegaly disease control. Pituitary (2011) 1.44
A consensus on the diagnosis and treatment of acromegaly complications. Pituitary (2013) 1.26
Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A (2007) 1.16
From somatostatin to octreotide LAR: evolution of a somatostatin analogue. Curr Med Res Opin (2009) 1.10
A genome-wide association study identifies novel loci associated with circulating IGF-I and IGFBP-3. Hum Mol Genet (2011) 1.10
Dual role for glucocorticoids in cardiomyocyte hypertrophy and apoptosis. Endocrinology (2012) 1.09
Resolution of acromegalic cardiomyopathy in mild acromegalic physical abnormality after short-term octreotide therapy. Heart Vessels (2007) 1.08
The changing face of acromegaly--advances in diagnosis and treatment. Nat Rev Endocrinol (2012) 1.03
Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) (2007) 0.95
Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol (Oxf) (2008) 0.92
Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol (2007) 0.92
Risk of neoplasms in acromegaly. Contemp Oncol (Pozn) (2012) 0.90
Pulmonary function testing and chest tomography in patients with acromegaly. Multidiscip Respir Med (2013) 0.90
Radiation techniques for acromegaly. Radiat Oncol (2011) 0.90
Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab (2014) 0.90
Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary (2011) 0.90
Gallbladder villous adenoma in a patient with acromegaly: a case report. World J Gastroenterol (2007) 0.89
Risk of thyroid nodular disease and thyroid cancer in patients with acromegaly--meta-analysis and systematic review. PLoS One (2014) 0.88
Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study. Pituitary (2014) 0.87
Limited effects of growth hormone replacement in patients with GH deficiency during long-term cure of acromegaly. Pituitary (2009) 0.87
Growth hormone and its disorders. Postgrad Med J (2006) 0.87
Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study. BMC Endocr Disord (2016) 0.86
Restrictive extraocular myopathy: a presenting feature of acromegaly. Indian J Ophthalmol (2011) 0.86
On the functional capacity and quality of life of patients with acromegaly: are they candidates for rehabilitation programs? J Phys Ther Sci (2013) 0.85
Growth hormone, prolactin, and sexuality. J Endocrinol Invest (2012) 0.84
Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases. Pituitary (2013) 0.84
Increased neck soft tissue mass and worsening of obstructive sleep apnea after growth hormone treatment in men with abdominal obesity. J Clin Sleep Med (2010) 0.84
The GH/IGF-1 Axis and Heart Failure. Curr Cardiol Rev (2009) 0.84
Prevalence of diabetes mellitus in patients with acromegaly. Endocr Connect (2014) 0.82
Macroscopic brain architecture changes and white matter pathology in acromegaly: a clinicoradiological study. Pituitary (2009) 0.82
Both low and high serum IGF-1 levels associate with increased risk of cardiovascular events in elderly men. J Clin Endocrinol Metab (2014) 0.82
Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary (2012) 0.82
Congestive heart failure in acromegaly: A review of 6 cases. Indian J Endocrinol Metab (2012) 0.82
Place of preoperative treatment of acromegaly with somatostatin analog on surgical outcome: a systematic review and meta-analysis. PLoS One (2013) 0.82
Reduced basal ATP synthetic flux of skeletal muscle in patients with previous acromegaly. PLoS One (2008) 0.82
Echocardiographic findings in 11 cats with acromegaly. J Vet Intern Med (2014) 0.82
New therapeutic agents for acromegaly. Nat Rev Endocrinol (2015) 0.81
Absence of periodontitis in acromegalic patients. Clin Oral Investig (2008) 0.81
Clinical effectiveness and cost-effectiveness of pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocr Disord (2009) 0.81
Perioperative management and complications in patients with obstructive sleep apnea undergoing transsphenoidal surgery: Our institutional experience. J Anaesthesiol Clin Pharmacol (2014) 0.81
Prevalence of osteoporosis and vertebral fractures in acromegalic patients. Clin Cases Miner Bone Metab (2011) 0.81
Elevated systolic blood pressure in male GH transgenic mice is age dependent. Endocrinology (2013) 0.81
Accelerated Telomere Shortening in Acromegaly; IGF-I Induces Telomere Shortening and Cellular Senescence. PLoS One (2015) 0.80
Cushing, acromegaly, GH deficiency and tendons. Muscles Ligaments Tendons J (2014) 0.80
Hand and foot abnormalities associated with genetic diseases. Hand (N Y) (2010) 0.80
Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? PLoS One (2014) 0.80
Adverse anthropometric risk profile in biochemically controlled acromegalic patients: comparison with an age- and gender-matched primary care population. Pituitary (2010) 0.80
Mutation analysis of aryl hydrocarbon receptor interacting protein (AIP) gene in colorectal, breast, and prostate cancers. Br J Cancer (2007) 0.80
Stereotactic Irradiation of GH-Secreting Pituitary Adenomas. Int J Endocrinol (2012) 0.79
Nanomedicines in the treatment of acromegaly: focus on pegvisomant. Int J Nanomedicine (2006) 0.79
Osteoarticular changes in acromegaly. Int J Endocrinol (2012) 0.79
Thyroid diseases in patients with acromegaly. Arch Med Sci (2013) 0.79
Neurocognitive function in acromegaly after surgical resection of GH-secreting adenoma versus naïve acromegaly. PLoS One (2013) 0.78
Challenges in the diagnosis and management of acromegaly: a focus on comorbidities. Pituitary (2016) 0.78
Glycemic profile in patients with acromegaly treated with somatostatin analogue. J Med Life (2015) 0.77
The Long Intron 1 of Growth Hormone Gene from Reeves' Turtle (Chinemys reevesii) Correlates with Negatively Regulated GH Expression in Four Cell Lines. Int J Mol Sci (2016) 0.77
Pasireotide: a novel treatment for patients with acromegaly. Drug Des Devel Ther (2016) 0.77
Long-term effects of pegvisomant on comorbidities in patients with acromegaly: a retrospective single-center study. Eur J Endocrinol (2015) 0.77
Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Rep (2010) 0.77
AHR over-expression in papillary thyroid carcinoma: clinical and molecular assessments in a series of Italian acromegalic patients with a long-term follow-up. PLoS One (2014) 0.77
Therapeutic options in the management of acromegaly: focus on lanreotide Autogel. Biologics (2008) 0.77
Using growth hormone levels to detect macroadenoma in patients with acromegaly. Endocrinol Metab (Seoul) (2014) 0.76
Surgery and radiosurgery for acromegaly: a review of indications, operative techniques, outcomes, and complications. Int J Endocrinol (2012) 0.76
Invasive Growth Hormone Producing Pituitary Adenoma With Lymphocytic Infiltration: A Case Report and Literature Review. Iran J Cancer Prev (2015) 0.76
Does attainment of target levels of growth hormone and insulin-like growth factor I improve acromegaly prognosis? Nat Clin Pract Endocrinol Metab (2009) 0.76
Clinical experiences and success rates of acromegaly treatment: the single center results of 62 patients. BMC Endocr Disord (2014) 0.76
The effect of disease control on mean platelet volume and red blood cell distribution in patients with acromegaly. Int J Clin Exp Med (2015) 0.76
Multiple facets in the control of acromegaly. Pituitary (2014) 0.76
Pharmacoeconomic aspects of the treatment of pituitary gland tumours. Contemp Oncol (Pozn) (2013) 0.76
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline. J Endocrinol Invest (2014) 0.76
What is the effect of peripheral muscle fatigue, pulmonary function, and body composition on functional exercise capacity in acromegalic patients? J Phys Ther Sci (2015) 0.75
A male patient with acromegaly and breast cancer: treating acromegaly to control tumor progression. BMC Cancer (2015) 0.75
Cardiovascular System Changes and Related Risk Factors in Acromegaly Patients: A Case-Control Study. Int J Endocrinol (2015) 0.75
Current therapies and mortality in acromegaly. J Med Life (2015) 0.75
No differences in metabolic outcomes between nadir GH 0.4 and 1.0 ng/mL during OGTT in surgically cured acromegalic patients (observational study). Medicine (Baltimore) (2016) 0.75
Three-dimensional soft tissue analysis of the hand: a novel method to investigate effects of acromegaly. Eur J Plast Surg (2016) 0.75
The association between biochemical control and cardiovascular risk factors in acromegaly. BMC Endocr Disord (2017) 0.75
Leptin Receptor Gene Polymorphism may Affect Subclinical Atherosclerosis in Patients with Acromegaly. Avicenna J Med Biotechnol (2016) 0.75
Risk of malignant neoplasms in acromegaly: a case-control study. J Endocrinol Invest (2016) 0.75
Rare causes of osteoporosis. Clin Cases Miner Bone Metab (2015) 0.75
Fractures in pituitary adenoma patients from the Dutch National Registry of Growth Hormone Treatment in Adults. Pituitary (2016) 0.75
Thyroid nodules in acromegaly: The role of elastography. J Ultrasound (2010) 0.75
Communication practices and awareness of resources for acromegaly patients among endocrinologists. Patient Prefer Adherence (2016) 0.75
CT pulmonary densitovolumetry in patients with acromegaly: a comparison between active disease and controlled disease. Br J Radiol (2015) 0.75
Functional changes are associated with tracheal structural abnormalities in patients with acromegaly. Arch Med Sci (2016) 0.75
A 52-year-old female with a hoarse voice and tingling in the hand. PLoS Med (2007) 0.75
Respiratory manifestations in endocrine diseases. Clujul Med (2016) 0.75
The risks of overlooking the diagnosis of secreting pituitary adenomas. Orphanet J Rare Dis (2016) 0.75
Pituitary adenomas in childhood and adolescence with a focus on intratumoral hemorrhage. Pituitary (2014) 0.75
Correlations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly. Braz J Med Biol Res (2015) 0.75
Implementing a screening program for acromegaly in Latin America: necessity versus feasibility. Pituitary (2016) 0.75
Case Report: A case report of acromegaly associated with primary aldosteronism. F1000Res (2014) 0.75
Clinical applications of somatostatin analogs for growth hormone-secreting pituitary adenomas. Patient Prefer Adherence (2014) 0.75
Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues. Endocr Connect (2016) 0.75
Body Image Disturbance in Acromegaly Patients Compared to Nonfunctioning Pituitary Adenoma Patients and Controls. Int J Endocrinol (2015) 0.75
A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary (2017) 0.75
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med (2002) 2.31
Advances in the treatment of prolactinomas. Endocr Rev (2006) 2.31
Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated colon and rectum tumour/carcinoma. Neuroendocrinology (2007) 2.27
Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased cardiovascular risk. J Clin Endocrinol Metab (2002) 2.15
Endocrine disorders during the first year after autologous stem-cell transplant. Am J Med (2005) 2.14
Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med (2003) 2.09
The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab (2004) 2.01
Evaluation of a multisensor armband in estimating energy expenditure in obese individuals. Obesity (Silver Spring) (2006) 1.85
Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol (2003) 1.79
The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) (2007) 1.73
Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res (2004) 1.67
BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos Int (2005) 1.61
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol (2005) 1.59
Traffic pollutants affect fertility in men. Hum Reprod (2003) 1.56
Comparison between ultrafast and standard single-photon emission CT in patients with coronary artery disease: a pilot study. Circ Cardiovasc Imaging (2010) 1.53
Metformin administration versus laparoscopic ovarian diathermy in clomiphene citrate-resistant women with polycystic ovary syndrome: a prospective parallel randomized double-blind placebo-controlled trial. J Clin Endocrinol Metab (2004) 1.53
Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab (2003) 1.52
Deconvolution-based assessment of pituitary GH secretion stimulated with GHRH+arginine in Prader-Willi adults and obese controls. Clin Endocrinol (Oxf) (2013) 1.48
Impact of attenuation correction and gated acquisition in SPECT myocardial perfusion imaging: results of the multicentre SPAG (SPECT Attenuation Correction vs Gated) study. Eur J Nucl Med Mol Imaging (2011) 1.46
Relationships between myocardial perfusion abnormalities and poststress left ventricular functional impairment on cadmium-zinc-telluride imaging. Eur J Nucl Med Mol Imaging (2015) 1.44
The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab (2008) 1.41
Clinical utility of estimated glomerular filtration rate in patients undergoing gated SPECT. J Nucl Cardiol (2009) 1.40
Cushing's Syndrome. Endocrinol Metab Clin North Am (2008) 1.33
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab (2005) 1.32
Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.31
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) (2004) 1.29
Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinology (2010) 1.28
Well-differentiated pancreatic tumor/carcinoma: insulinoma. Neuroendocrinology (2007) 1.21
Resistance to somatostatin analogs in acromegaly. Endocr Rev (2010) 1.20
Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab (2006) 1.20
Thyroid nodules and related symptoms are stably controlled two years after radiofrequency thermal ablation. Thyroid (2009) 1.16
HMGA proteins up-regulate CCNB2 gene in mouse and human pituitary adenomas. Cancer Res (2009) 1.16
Prolactin and autoimmunity. Pituitary (2005) 1.15
Deep subcutaneous adipose tissue: a distinct abdominal adipose depot. Obesity (Silver Spring) (2007) 1.15
Medical therapy for clinically non-functioning pituitary adenomas. Endocr Relat Cancer (2008) 1.13
Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J Clin Endocrinol Metab (2008) 1.13
Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab (2005) 1.13
High diagnostic accuracy of low-dose gated-SPECT with solid-state ultrafast detectors: preliminary clinical results. Eur J Nucl Med Mol Imaging (2011) 1.13
Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J Clin Endocrinol Metab (2004) 1.12
The metabolic syndrome and cardiovascular risk in Cushing's syndrome. Endocrinol Metab Clin North Am (2005) 1.12
Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review. Cancer (2003) 1.11
Differences of myocardial systolic deformation and correlates of diastolic function in competitive rowers and young hypertensives: a speckle-tracking echocardiography study. J Am Soc Echocardiogr (2010) 1.09
Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab (2004) 1.08
High prevalence of endocrine dysfunction in long-term survivors after allogeneic bone marrow transplantation for hematologic diseases. Cancer (2002) 1.08
The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome. J Clin Endocrinol Metab (2004) 1.07
Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities. Acta Diabetol (2009) 1.07
Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study. Clin Endocrinol (Oxf) (2003) 1.06
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab (2006) 1.06
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol (2006) 1.05
Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf) (2007) 1.05
Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors. Ann Surg (2007) 1.05
The kidney in acromegaly: renal structure and function in patients with acromegaly during active disease and 1 year after disease remission. Eur J Endocrinol (2010) 1.04
Subclinical hypothyroidism and cardiovascular risk: a reason to treat? Treat Endocrinol (2004) 1.03
Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab (2002) 1.02
Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. J Clin Endocrinol Metab (2007) 1.02
A fast and effective method to assess myocardial necrosis by means of contrast magnetic resonance imaging. J Cardiovasc Magn Reson (2005) 1.02
Colonoscopic screening and follow-up in patients with acromegaly: a multicenter study in Italy. J Clin Endocrinol Metab (2004) 1.01
Overexpression of stromal cell-derived factor 1 and its receptor CXCR4 induces autocrine/paracrine cell proliferation in human pituitary adenomas. Clin Cancer Res (2008) 1.01
Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly. Clin Endocrinol (Oxf) (2008) 1.00
Relationships between serum IGF1 levels, blood pressure, and glucose tolerance: an observational, exploratory study in 404 subjects. Eur J Endocrinol (2008) 1.00
Subclinical hyperthyroidism: clinical features and treatment options. Eur J Endocrinol (2005) 0.99
Novel insights in dopamine receptor physiology. Eur J Endocrinol (2007) 0.99
Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. Hum Reprod (2007) 0.99
Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study. Clin Endocrinol (Oxf) (2006) 0.99
Assessment of myocardial adrenergic innervation with a solid-state dedicated cardiac cadmium-zinc-telluride camera: first clinical experience. Eur Heart J Cardiovasc Imaging (2013) 0.99
Evaluation of ischaemia in obese patients: feasibility and accuracy of a low-dose protocol with a cadmium-zinc telluride camera. Eur J Nucl Med Mol Imaging (2012) 0.99
Bone loss and its management in long-term survivors from allogeneic stem cell transplantation. J Clin Endocrinol Metab (2007) 0.98
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab (2007) 0.97
Ultrasound-guided laser thermal ablation in the treatment of autonomous hyperfunctioning thyroid nodules and compressive nontoxic nodular goiter. Thyroid (2003) 0.96
Andrenocortical carcinomas: twelve-year prospective experience. World J Surg (2004) 0.96
Therapy of aggressive pituitary tumors. Expert Opin Pharmacother (2011) 0.95
Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab (2004) 0.95
Identification of a novel mutation in exon 1 of androgen receptor gene in an azoospermic patient with mild androgen insensitivity syndrome: case report and literature review. Fertil Steril (2011) 0.95
Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab (2006) 0.95
Cardiovascular risk in women with polycystic ovary syndrome. J Cardiovasc Med (Hagerstown) (2008) 0.94
Ovarian size and blood flow in women with polycystic ovary syndrome and their correlations with endocrine parameters. Fertil Steril (2005) 0.94
Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab (2005) 0.93
Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine (2003) 0.93
Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation. J Clin Endocrinol Metab (2004) 0.93
Adiponectin levels in women with polycystic ovary syndrome. J Clin Endocrinol Metab (2003) 0.93
Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab (2012) 0.93
A reappraisal of diagnosing GH deficiency in adults: role of gender, age, waist circumference, and body mass index. J Clin Endocrinol Metab (2009) 0.93
Feasibility and diagnostic accuracy of a gated SPECT early-imaging protocol: a multicenter study of the Myoview Imaging Optimization Group. J Nucl Med (2007) 0.93
Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure. J Clin Endocrinol Metab (2003) 0.93
Effects of initial therapy for five years with somatostatin analogs for acromegaly on growth hormone and insulin-like growth factor-I levels, tumor shrinkage, and cardiovascular disease: a prospective study. J Clin Endocrinol Metab (2009) 0.93
Cushing's syndrome: aftermath of the cure. Arq Bras Endocrinol Metabol (2007) 0.93
Antiproliferative and proapoptotic effects of raloxifene on uterine leiomyomas in postmenopausal women. Fertil Steril (2005) 0.92
Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Treat Endocrinol (2004) 0.92
Stress/Rest Myocardial Perfusion Abnormalities by Gated SPECT: Still the Best Predictor of Cardiac Events in Stable Ischemic Heart Disease. J Nucl Med (2009) 0.92
Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation. J Clin Endocrinol Metab (2002) 0.92
Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. Growth Horm IGF Res (2006) 0.92
Exercise training improves autonomic function and inflammatory pattern in women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) (2008) 0.92
Severe impairment of bone mass and turnover in Cushing's disease: comparison between childhood-onset and adulthood-onset disease. Clin Endocrinol (Oxf) (2002) 0.91